Do analysts prefer CPHI or UTZ?

Utz Brands has a consensus target price of $13.39, suggesting a potential downside of 5.26%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts plainly believe Utz Brands is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Utz Brands 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CPHI or UTZ more profitable?

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Utz Brands -2.00% 8.97% 4.32%

Do analysts rate CPHI or LFCR?

Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 43.17%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lifecore Biomedical 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer CPHI or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CPHI or MENS?

China Pharma has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China Pharma $3.91M 10.77 -$3.08M -$0.43 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts recommend CPHI or LENZ?

LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 515.38%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

China Pharma (CPHI) Competitors

$0.98 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

CPHI vs. UTZ, LFCR, MENS, UNCY, and LENZ

Should you buy China Pharma stock or one of its competitors? China Pharma's main competitors and comparable companies include Utz Brands (UTZ), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Unicycive Therapeutics (UNCY), and LENZ Therapeutics (LENZ). Companies are selected based on similarities in market, industry, and size.

How does China Pharma compare to Utz Brands?

China Pharma (NYSE:CPHI) and Utz Brands (NYSE:UTZ) are related companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Utz Brands has a consensus target price of $13.39, suggesting a potential downside of 5.26%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts plainly believe Utz Brands is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Utz Brands	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.0% of Utz Brands shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 12.7% of Utz Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Utz Brands had 7 more articles in the media than China Pharma. MarketBeat recorded 7 mentions for Utz Brands and 0 mentions for China Pharma. Utz Brands' average media sentiment score of 0.36 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Utz Brands	Neutral

China Pharma has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Utz Brands has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Utz Brands has higher revenue and earnings than China Pharma. Utz Brands is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A
Utz Brands	$1.44B	1.41	$800K	-$0.33	N/A

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Utz Brands	-2.00%	8.97%	4.32%

Summary

Utz Brands beats China Pharma on 13 of the 16 factors compared between the two stocks.

How does China Pharma compare to Lifecore Biomedical?

China Pharma (NYSE:CPHI) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Lifecore Biomedical had 2 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Lifecore Biomedical and 0 mentions for China Pharma. Lifecore Biomedical's average media sentiment score of 1.31 beat China Pharma's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Lifecore Biomedical	Positive

83.4% of Lifecore Biomedical shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 43.17%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

China Pharma has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A

Lifecore Biomedical has a net margin of -29.93% compared to China Pharma's net margin of -85.56%. Lifecore Biomedical's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Lifecore Biomedical	-29.93%	N/A	-16.16%

China Pharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Summary

Lifecore Biomedical beats China Pharma on 12 of the 16 factors compared between the two stocks.

How does China Pharma compare to Jyong Biotech?

China Pharma (NYSE:CPHI) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, China Pharma's average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
China Pharma	Neutral
Jyong Biotech	Neutral

Jyong Biotech has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Jyong Biotech's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Jyong Biotech	N/A	N/A	N/A

China Pharma has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

China Pharma has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Summary

Jyong Biotech beats China Pharma on 5 of the 7 factors compared between the two stocks.

How does China Pharma compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

China Pharma has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A

In the previous week, Unicycive Therapeutics had 3 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for China Pharma. Unicycive Therapeutics' average media sentiment score of 0.76 beat China Pharma's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Positive
China Pharma	Neutral

Unicycive Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
China Pharma	-85.56%	-63.93%	-31.42%

Unicycive Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 233.04%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Unicycive Therapeutics beats China Pharma on 9 of the 16 factors compared between the two stocks.

How does China Pharma compare to LENZ Therapeutics?

China Pharma (NYSE:CPHI) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

54.3% of LENZ Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 515.38%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

China Pharma has higher earnings, but lower revenue than LENZ Therapeutics. China Pharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A
LENZ Therapeutics	$19.09M	7.70	-$82.13M	-$4.09	N/A

In the previous week, LENZ Therapeutics had 2 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for China Pharma. LENZ Therapeutics' average media sentiment score of 0.51 beat China Pharma's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
LENZ Therapeutics	Positive

China Pharma has a net margin of -85.56% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Summary

LENZ Therapeutics beats China Pharma on 10 of the 16 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$42.16M	$12.49B	$7.32B	$24.24B
Dividend Yield	N/A	2.62%	2.54%	3.70%
P/E Ratio	-2.28	789.80	272.91	30.31
Price / Sales	10.77	795.45	639.20	20.18
Price / Cash	N/A	15.47	29.03	19.80
Price / Book	1.40	10.52	11.38	4.90
Net Income	-$3.08M	$2.81B	$3.47B	$1.07B
7 Day Performance	-9.26%	2.49%	2.16%	0.02%
1 Month Performance	-35.53%	5.06%	7.59%	3.10%
1 Year Performance	-34.27%	7.26%	25.16%	14.90%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.98 flat	N/A	-34.3%	$42.16M	$3.91M	N/A	250	Gap Up
UTZ Utz Brands	2.3899 of 5 stars	$14.14 -0.1%	$13.39 -5.3%	+6.0%	$2.04B	$1.44B	N/A	3,300
LFCR Lifecore Biomedical	1.8981 of 5 stars	$4.52 +1.3%	$6.50 +43.8%	-40.3%	$168.82M	$128.87M	N/A	690	Positive News
MENS Jyong Biotech	N/A	$2.16 +3.8%	N/A	-95.3%	$158.14M	N/A	N/A	31
UNCY Unicycive Therapeutics	3.2215 of 5 stars	$5.45 -2.3%	$18.75 +244.0%	+34.0%	$155.43M	$680K	N/A	9	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. UTZ, LFCR, MENS, UNCY, and LENZ

How does China Pharma compare to Utz Brands?

Summary

How does China Pharma compare to Lifecore Biomedical?

Summary

How does China Pharma compare to Jyong Biotech?

Summary

How does China Pharma compare to Unicycive Therapeutics?

Summary

How does China Pharma compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. UTZ, LFCR, MENS, UNCY, and LENZ

How does China Pharma compare to Utz Brands?

Do analysts prefer CPHI or UTZ?

Do institutionals and insiders have more ownership in CPHI or UTZ?

Does the media favor CPHI or UTZ?

Which has more risk & volatility, CPHI or UTZ?

Which has higher valuation & earnings, CPHI or UTZ?

Is CPHI or UTZ more profitable?

Summary

How does China Pharma compare to Lifecore Biomedical?

Does the media refer more to CPHI or LFCR?

Do insiders and institutionals have more ownership in CPHI or LFCR?

Do analysts rate CPHI or LFCR?

Which has stronger earnings & valuation, CPHI or LFCR?

Is CPHI or LFCR more profitable?

Which has more volatility and risk, CPHI or LFCR?

Summary

How does China Pharma compare to Jyong Biotech?

Do analysts prefer CPHI or MENS?

Does the media favor CPHI or MENS?

Is CPHI or MENS more profitable?

Which has more risk & volatility, CPHI or MENS?

Which has stronger valuation and earnings, CPHI or MENS?

Summary

How does China Pharma compare to Unicycive Therapeutics?

Which has preferable valuation & earnings, UNCY or CPHI?

Does the media prefer UNCY or CPHI?

Is UNCY or CPHI more profitable?

Do analysts prefer UNCY or CPHI?

Do institutionals and insiders hold more shares of UNCY or CPHI?

Which has more volatility and risk, UNCY or CPHI?

Summary

How does China Pharma compare to LENZ Therapeutics?

Do insiders and institutionals hold more shares of CPHI or LENZ?

Do analysts recommend CPHI or LENZ?

Which has better earnings & valuation, CPHI or LENZ?

Does the media favor CPHI or LENZ?

Is CPHI or LENZ more profitable?

Which has more volatility and risk, CPHI or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools